PERINATOLOGIYA AND PEDIATRIYA.2019.2(78):46-50; doi 10.15574/PP.2019.78.46

Abaturov О. Ye., Vysochyna I. L., Tokarieva N. M.
SI «Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine», Dnipro

Purpose — to develop and study the effectiveness of the author's algorithm of differential choice as regards medicines in the inpatient therapy for acute bronchitis in children.

Patients and methods. On the basis of correlation analysis and sequential Wald's analysis, the algorithm of differential choice of medicines (recombinant interferon alpha-2β; probiotical agent Bacillus subtilis; bacterial lysates OM-85; Ivy extract) which are to be used in management of children with acute simple bronchitis (ASB) was developed. The differential administration of medicines for management of ASB in children was shown to lead to the faster resolution of catarrhal and inflammatory syndromes, as well as contribute to the restoration of non-specific immunity indicators. The results of introduction of the algorithm of doctor's actions into healthcare practice have demonstrated that the estimated effectiveness of usage and likelihood of acquiring the final result are equal to 75–86%.

Conclusions. Features of functioning of the system of non-specific respiratory tract defense in children of 1 to 6 years old with ASB, their clinical and anamnestic characteristics, as well as dynamics of ASB course according to BSS justify the necessity to reinforce standard inpatient therapy of ASB. The administration of recombinant interferon, probiotical agents, bacterial lysates and Ivy extract for children of 1to 6 years old with ASB in order to restore non-specific immunity was pathogenetically justified based on proved clinical and immunologic effectiveness along with their influence on major clinical signs of acute bronchitis according to Bronchitis severity score (BSS).

Key words: acute bronchitis, children, algorithm of differential treatment.

REFERENCES

1. Abaturov AE, Kryuchko TA, Agafonova EA еt al. Probiotiki and medical praktika. Kharkov: Planeta-Print: 128.

2. Abaturov AE, Yulish EI. (2007). The role of interferon in the protection of the respiratory tract. Part 1. Cascade of excitation of the interferon system. Child Health. 5 (8): 71—76.

3. Abaturov AE, Tokareva NM. (2018). Efficiency of probiotic bacteria Bacillus subtilis for acute nonobstructive bronchitis treatment in children. Sovremennaya pediatriya. 6 (94): 78—83. https://doi.org/10.15574/SP.2018.94.78

4. Ahafonova OO, Tokarieva NM.(2019) Prediction of the risk of developing a long course of acute bronchitis in children. Child Health. 14 (3): 19—23. https://doi.org/10.22141/2224-0551.14.3.2019.168766

5. Dzhumagaziev AA. (2016). Use of imunomodulyators and metabolites for the prophylaxis of acute bronchitis and acute pneumonia in children. New science: Theoretical and practical look. 117 (3): 44—45.

6. Zaytsev AA. (2017). Acute respiratory viral infections: pressing questions of diagnostics, treatments and preventions. Practical recommendations. Moscow: 240.

7. Kryuchko TO, Abaturov OE, Tkachenko OY, Tokarieva NM. (2018).  Children have priority of application of fitopreparativ in treatment of viral respiratory infections. Child's health. 1 (13): 59—65. https://doi.org/10.22141/2224-0551.13.1.2018.127062.

8. Lyisenko IM, Barkun GK, Zhuravleva LN et al. (2016). Etiopatogenetic aspects of therapy of diseases of respiratory highway for children and teenagers. Guard of maternity and childhood. 2 (28): 35—57.

9. Suhorukova DN, Kuznetsova TA. (2016). Epidemiology of acute bronchitis and bronchiolitis at children. The Eurasian union of scientists. 32: 19—21.

10. Chernyisheva OE. (2016). Application of rekombinant  α2b -interferona in treatment of acute respiratory viral diseases at children. Child's health. 6 (74): 69—73. https://doi.org/10.22141/2224-0551.6.74.2016.82135

11. Yulish EI. (2013). Antiviral therapy in the treatment of acute respiratory diseases in children. Sovremennaya pediatriya. 5(53): 75—79. doi 10.15574/SP.2013.53.75

12. Alkaya B, Laleman I, Keceli S. et al. (2017, Jun.). Clinical effects of probiotics containing Bacillus species on gingivitis: a pilot randomized controlled trial. J. Periodontal. Res. 52 (3): 497—504. https://doi.org/10.1111/jre.12415; PMid:27859252.

13. Berlutti F, Pantanella F, Natalizi T et al. (2011, Aug.). Antiviral properties of lactoferrin-a natural immunity molecule. Molecules. 16 (8): 6992—7018. https://doi.org/10.3390/molecules16086992; PMid:21847071 PMCid:PMC6264778.

14. Bo L, Tao T et al. (2014, Oct.). Probiotics for preventing ventilator-associated pneumonia. Cochrane Database Syst Rev. 25; (10):CD009066. https://doi.org/10.1002/14651858.CD009066.pub2; PMCid:PMC4283465.

15. Cook DJ, Johnstone J, Marshall JC et al. (2016, Aug.). Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial-PROSPECT: a pilot trial. Trials. 2; 17: 377. https://doi.org/10.1186/s13063-016-1495-x; PMid:27480757 PMCid:PMC4970233.

16. Gualdi L, Mertz S, Gomez AM et al. (2013, Aug.). Lack of effect of bovine lactoferrin in respiratory syncytial virus replication and clinical disease severity in the mouse model. Antiviral Res. 99 (2): 188—195. https://doi.org/10.1016/j.antiviral.2013.05.013; PMid:23735300.

17. Kardos P, Lehrl S, Kamin W, Matthys H. (2014, Aug.). Assessment of the effect of pharmacotherapy in common cold/acute bronchitis — the Bronchitis Severity Scale. Pneumologie. 68 (8): 542—546. https://doi.org/10.1055/s-0034-1377332; PMid:25003904.

18. Lefevre M, Racedo SM, Ripert G et al. (2015, Dec.). Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Immun. Ageing. 3; 12: 24. https://doi.org/10.1186/s12979-015-0051-y; PMid:26640504 PMCid:PMC4669646.

19. Lefevre M, Racedo SM, Denayrolles M et al. (2017, Feb.). Safety assessment of Bacillus subtilis CU1 for use as a probiotic in humans. Regul. Toxicol. Pharmacol. 83: 54—65. https://doi.org/10.1016/j.yrtph.2016.11.010; PMid:27825987.

20. Moawad EM, Haron MA, Maher RM et al. (2017, Mar.). Cross-sectional evaluation of the Bronchitis Severity Score in Egyptian children: A move to reduce antibiotics. S. Afr. Med. J. 29. 107 (4): 342—345. https://doi.org/10.7196/SAMJ.2017.v107i4.11428; PMid:28395688.

Article received: Feb 02, 2019. Accepted for publication: Jun 05, 2019.